VolitionRx Achieves Technical Milestone in Sepsis Detection with Finger-Prick Prototype
VolitionRx announced a prototype that can detect nucleosomes in capillary blood from sepsis patients, potentially enabling point-of-care testing and expanding access in regions with limited lab infrastructure.
VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company, announced a technical milestone in the detection of nucleosomes in capillary blood from critically ill patients with sepsis using a lateral flow finger-prick prototype. The study, conducted as part of the SUMMIT program, demonstrated the feasibility of detecting nucleosomes in capillary samples, supporting the potential for early detection of immune disruptions associated with conditions such as sepsis across point-of-care and non-laboratory settings.
The prototype builds on prior results showing correlation between venous blood samples tested with its lateral flow system and its established Nu.Q nucleosome assay. According to the company, this approach could expand access to testing through point-of-care use and broaden its addressable market while supporting future commercialization efforts, including potential partnerships to increase access in regions with limited laboratory infrastructure. The findings are significant because sepsis is a life-threatening condition that requires rapid diagnosis and treatment; early detection can improve patient outcomes and reduce healthcare costs.
VolitionRx is focused on advancing the science of epigenetics, developing simple, easy-to-use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. The company’s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. For more information, visit the company’s website at www.Volition.com.
The full press release is available at https://ibn.fm/ioEmu.
This development is important because it addresses a critical need for rapid, accessible diagnostic tools in sepsis management. The ability to use a simple finger-prick test, rather than relying on venous blood draws and laboratory analysis, could revolutionize sepsis detection in emergency departments, intensive care units, and even remote or resource-limited settings. By enabling earlier intervention, this technology has the potential to save lives and reduce the burden on healthcare systems worldwide.
VolitionRx’s progress in this area also highlights the broader potential of nucleosome detection as a biomarker for immune dysregulation. The company’s Nu.Q assay has already been validated for venous samples, and this new prototype extends its utility to capillary blood, which is easier to collect and process. As VolitionRx continues to develop and commercialize its technologies, it may also explore partnerships to accelerate adoption in underserved markets.